We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Precision BioSciences Inc | NASDAQ:DTIL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.84 | 9.50 | 9.98 | 0 | 01:00:00 |
H.C. Wainwright Global Life Sciences Conference Date: Tuesday, March 9, 2021 The fireside chat will be available on demand beginning at 7:00 AM ET with an archived replay available for 90 days.
Barclays Global Healthcare Conference Date: Tuesday, March 9, 2021 Presentation: 10:55 AM ET An archived replay of this corporate presentation will be available for one year.
Webcasts will be accessible on the Company’s website, www.precisionbiosciences.com, in the Investors & Media section under Events and Presentations.
About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
Investor Contact: Alex Kelly Interim Chief Financial Officer Alex.Kelly@precisionbiosciences.com
Media Contact: Maurissa Messier Senior Director, Corporate Communications Maurissa.Messier@precisionbiosciences.com
1 Year Precision BioSciences Chart |
1 Month Precision BioSciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions